BGB-A445 is a humanized non-ligand blocking agonistic OX40 monoclonal antibody with high affinity for OX40. It activates the downstream NF-kappaB pathway, inducing activation, proliferation, and survival of immune cells. BGB-A445 significantly depletes regulatory T cells in a dose-dependent manner via antibody-dependent cellular cytotoxicity (ADCC). In the MC38 mouse model, BGB-A445 demonstrates potent, dose-dependent antitumor efficacy and is applicable in cancer studies, such as colorectal adenocarcinoma.
CAS Nummer:
[3033874-57-3]
Target-Kategorie:
OX Receptor|||NF-kappaB
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
